• Product NameLumacaftor(VX 809)
• Brief DescriptionInhibitors
• Purification99.68%
• Biological ActivityVX-809 (Lumacaftor) acts to correct CFTR mutations common in cystic fibrosis by increasing mutant CFTR (F508del-CFTR) maturation,EC50 of 0.1 μM in fisher rat thyroid cells. Phase 3.
• Target NameCFTR modulator
• CAS No. 936727-05-8
• Calculated MW 452.41
• Formulation C24H18F2N2O5
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CC1=C(N=C(NC(=O)C2(CC2)C2=CC3=C(OC(F)(F)O3)C=C2)C=C1)C1=CC(=CC=C1)C(O)=O
  Pathways:Membrane transporter/Ion channel
  Receptor:F508del-CFTR
  Boling pt:
  Melting pt:
  Solubility:Ethanol: 6 mg/mL (13.26 mM); DMSO: 90 mg/mL (198.93 mM)
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Van Goor F, et al. Proc Natl Acad Sci U S A, 2011, 108(46), 18843-18848.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting